tirzepatide and heart disease UC Irvine researchers project cardiac benefits from weight-loss medication How the weight loss drug

The study "Liraglutide versus placebo as an adjunct to glucose-lowering therapy in patients with type 2 diabetes and moderate renal failure" (LIRA-RENAL) did not demonstrate a benefit of liraglutide in lowering eGFR, although the duration of the study (26 weeks) may have been insufficient to show an effect

That story you've been waiting for

This is not recommended for breastfeeding mothers.

Adverse Events 7.2mg vs 2.4mg Overall adverse events: 87.5% vs 84.1% Mild: 80.2% vs 76.6% Moderate: 50.4% vs 48.3% Severe: 8.1% vs 10.4% Serious: 6.8% vs 10.9% First of all, Ive heard some folks have confusion about the difference between severe and serious adverse events so I wanted to take a moment on this

Maintain a rotation schedule and avoid any given spot for at least 4 weeks